Related references
Note: Only part of the references are listed.Trends in kinase drug discovery: targets, indications and inhibitor design (Aug, 10.1038/s41573-021-00252-y, 2021)
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Nailing Down a Notoriously Elusive Cancer Target: Direct Inhibition of MYC by a Covalent Small Molecule
Matthew J. Henley et al.
CELL CHEMICAL BIOLOGY (2021)
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Robin A. Fairhurst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients
Christian Gampe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Covalent inhibitors: a rational approach to drug discovery
Fandi Sutanto et al.
RSC MEDICINAL CHEMISTRY (2020)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
Terry Podoll et al.
DRUG METABOLISM AND DISPOSITION (2019)
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Matthias Gehringer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
Liyang Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
Zhan Zhou et al.
CHEMICAL COMMUNICATIONS (2019)
Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors
Franck Amblard et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Progress with covalent small-molecule kinase inhibitors
Zheng Zhao et al.
DRUG DISCOVERY TODAY (2018)
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold
Michael Forster et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4
Thomas Knoepfel et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
Daichao Wu et al.
CHEMICAL COMMUNICATIONS (2018)
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors
Agustin Casimiro-Garcia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Covalent inhibitors: an opportunity for rational target selectivity
Roman Lagoutte et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
The drug-target residence time model: a 10-year retrospective
Robert A. Copeland
NATURE REVIEWS DRUG DISCOVERY (2016)
Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer
Julian Engel et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Targeting biomolecules with reversible covalent chemistry
Anupam Bandyopadhyay et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
Jeff B. Smaill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
Renato A. Bauer
DRUG DISCOVERY TODAY (2015)
Development of Selective Covalent Janus Kinase 3 Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
Molecular Mechanisms of Aldehyde Toxicity: A Chemical Perspective
Richard M. LoPachin et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Afatinib: First Global Approval
Rosselle T. Dungo et al.
DRUGS (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Reversible Covalent Inhibition of a Protein Target
Chang-Uk Lee et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Tjeerd Barf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Measurement and Estimation of Electrophilic Reactivity for Predictive Toxicology
Johannes A. H. Schwoebel et al.
CHEMICAL REVIEWS (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Characterization of HKI-272 Covalent Binding to Human Serum Albumin
Jianyao Wang et al.
DRUG METABOLISM AND DISPOSITION (2010)
Strategies for discovering and derisking covalent, irreversible enzyme inhibitors
Douglas S. Johnson et al.
FUTURE MEDICINAL CHEMISTRY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Peptide inhibitors of dengue virus NS3 protease. Part 1: Warhead
Z Yin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Drug bioactivation, covalent binding to target proteins and toxicity relevance
SF Zhou et al.
DRUG METABOLISM REVIEWS (2005)
Protein kinase inhibitors as a therapeutic modality
A Levitzki
ACCOUNTS OF CHEMICAL RESEARCH (2003)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Share Paper
